http://www.reportlinker.com/p0181059/Global-Nanobiotechnology-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nanotechn
This report analyzes the worldwide markets for Nanobiotechnology in US$ Million by the following Technology Segments: Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, & Other Nanomaterials), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 117 companies including many key and niche players worldwide such as Aduro BioTech, Arrowhead Research Corporation, Calando Pharmaceuticals, Inc., Agilent Technologies Inc., Asklepios BioPharmaceutical Inc., Biosante Phosphate Pharmaceuticals, Inc., Celgene Corporation, Elan Pharmaceuticals, Elitech Group, Flamel Technologies, Inc., Gilead Sciences Inc., Life Technologies Corporation, NanoBio Corporation, Nanogen, Inc., Nanophase Technologies Corporation, pSivida Ltd., Sigma Aldrich Company, Starpharma Holdings Ltd., Dendritic Nanotechnologies, Inc., SkyePharma Pharmaceuticals, Unidym, Inc., and Zyvex Instruments LLC. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-3Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-31. Nanomaterials I-4Solid Inorganic Nanoparticles I-4Nanocomposites I-4Nanostructured Materials and Membranes I-4Nanotubes and Fullerenes I-4Other Nanomaterials I-4Nanoshells I-4Nanohorns I-5Nanocapsules I-52. Nanodevices/Tools I-5II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
A Curtain Raiser II-1
Nanobiotechnology - The Next Big Thing II-2
Nanotechnology & Biology Tie the Knot: "Two to Tango" II-4
Where Conventional Molecular Science Falls Short Nanobio
Steps In II-4
What's The Obsession With Size? II-5
Why Analysis at the Cellular Level is Important? II-5
Lessons from Nature II-6
Dawn Breaks On Nanobiotechnology II-6
Table 1: Nanobiotechnology and Related Medical Applications
Market (2007): Percentage Share Breakdown of Activity
Distribution by Region and Organizational Set-Up (includes
corresponding Graph/Chart) II-7
Table 2: Percentage Breakdown of Number of NanotechnologyCompanies in Healthcare Industry Worldwide by Region/Country(2008) (includes corresponding Graph/Chart) II-7
Table 3: Percentage Breakdown of Number of Nanotechnology
Companies in Healthcare Industry Worldwide by Type - Private
and Public Sector (2008) (includes corresponding Graph/Chart) II-7
Table 4: Percentage Breakdown of Number of NanotechnologyCompanies in Healthcare Industry Worldwide By Sector -Therapeutics and Drug Delivery; Clinical Diagnostics; DrugDiscovery Tools and Biomedical Research; and Biomaterials andBiomedical Implants (2008) (includes correspondingGraph/Chart) II-8
Table 5: Percentage Breakdown of Number of Nanotechnology
Companies in The field of Therapeutics and Drug Delivery
Worldwide by Area - Targeted Nanoparticles, Solubility &
Reformulation, Sustained Release, Blood Brain Barrier,
Nanomaterial Therapeutics and Others (2008) (includes
corresponding Graph/Chart) II-8
Table 6: Percentage Breakdown of Number of NanotechnologyCompanies in the field Therapeutics Worldwide by TherapeuticArea - Oncology, Infectious Diseases, Central Nervous SystemDiseases, Nutraceuticals, Ophthalmology and Others (2008)(includes corresponding Graph/Chart) II-9
Table 7: Percentage Breakdown of Number of Nanotechnology
Companies in the field of Clinical Imaging and Diagnostics
Worldwide by Area - Tags and Probes; Imaging Agents;
Biosensors and Bio-detection; and Instruments (2008)
(includes corresponding Graph/Chart) II-9
Demystifying the Intriguing World of Nanobiotech II-9
A Meeting Place of Medicine's Best Solutions II-10
Nanobiotechnology Promises to Deliver Nanomedicine II-11
Nanobiotechnology to Become Viable for All Drug Development
Stages II-12
Nanobioproducts in R&D As of 2007 & 2008 II-13
List of Marketed Nanoparticle-Based Pharmaceutical Products
As of the Year 2007 II-13
Nanoparticles: The Foundation of Nanobiotechnology II-14
Improved Optical Properties and Stability of Nanoparticles II-14
Nanoemulsions II-15
Diagnosis & Treatment of Cancer II-15
The Promise of Nanobiotechnology II-16
Biological Weaponries Against Diseases Come in Small Packages II-16
Proffered Benefits of Nanobiotechnology II-17
Opportunity & Beyond II-17
Nanobiotechnology - Will it Live Up to the Expectations? II-18
The Future of Nanobiotechnology: Shape of Things to Come II-18
Nanobiotechnology: The Outer Limits II-18
Futuristics: A Rumination II-19
Nanobiotechnology In the Year 2015 II-20
Field of Nanodiagnostics II-20
Field of Regenerative Medicine II-20
Field of Targeted Drug Delivery II-20
Conclusions II-20
2. MARKET DYNAMICS II-21Nanotechnology & the 2007-2009 Recession: A Review II-21Nanobio Feels the Pinch or Does It ? : A Closer Look II-21Will Growth in Europe Be Held Hostage by the Debt Crisis? II-22Outlook II-22Developing Countries to Rise Over the Horizon II-22Table 8: Global Nanobiotechnology Market (2009): PercentageShare Breakdown of Investments by Region (includescorresponding Graph/Chart) II-23
Table 9: Worldwide Funding in Nanotechnology (2005 & 2010):
Percentage Breakdown of Value Investments by Region/Country:
A Comparison (includes corresponding Graph/Chart) II-23
Nanomaterials & Nanoparticles Witness Robust Activity II-24
Focus on Improved Performance to Bring New Manufacturing
Methods for Nanomaterials II-24
Private & Public Companies to Step Up Funding on Nanotechnology II-24
Table 10: Worldwide Government Funding in Nanotechnology
(2008-2015) (In US$ Billion) (includes corresponding
Graph/Chart) II-25
Increasing Awareness on Technology to Drive Growth II-25
Demand for Novel Products to Push Up Growth II-26
Nano-Enabled Drug Discovery Holds Tremendous Potential II-26
Consolidation Sharpens the Industry's Edge II-26
The Regulatory Framework Evolves with the Technology II-26
Quantum Dot Patents Pose Legal Tangles II-27
Miniaturized Liquid Handling Becomes Progressive II-27
Trends in Nanotechnology Enabled Drug Delivery Systems II-28
Robust Growth On Cards II-28
Table 11: Global Nanotechnology-Enabled Drug Delivery
Systems Market (2015 (P)): Percentage Share Breakdown of
Nanoparticles, Dendrimers, Polymer Therapeutics and Other
Nanostructures (includes corresponding Graph/Chart) II-28
Patent Expiries: A Key Driver II-29
Nanotechnology Enabled Drug Delivery to Exhume Unused Drugs II-29
3. INDUSTRY CHALLENGES & ISSUES II-30Challenges II-30Commercial Exploration: A Treacherous Voyage II-31Conventional Medicine to Contest Nanomedicine Adoption II-31Nanomaterials Use: Weighed Down with Toxicity Concerns II-32Production Issues Continue to Plague Nanobiotech Industry II-33Lack of De Facto Standards: A Challenge to Reckon With II-33Embroilment Over Ethical Issues II-34Social Relevance II-35Economic Relevance II-36
4. INDUSTRY STRUCTURE II-37
Industry Structure: A Quick Primer II-37
A Dissection of Select Segments II-37
Nanoparticles II-37
Nanotubes and Fullerenes II-38
Dendrimers II-38
A Peek Into the Regulatory Framework II-38
United States II-39
Europe II-39
A Closer Look at Regional Nano Efforts II-39
United States: Unraveling the Country's Edge II-39
Table 12: Global Intellectual Property Rights in
Nanotechnology by Leading Countries (2007) (includes
corresponding Graph/Chart) II-40
Europe: Hot On the Heels of the US II-40
Germany II-41
France II-41
United Kingdom II-41
Scandinavia II-41
Japan: A Noteworthy Region II-42
5. NANOBIO'S EPOCHAL STRIDES IN MODERN MEDICINE II-43A Primer II-43Impact on Drug Delivery Systems II-43Benefits Offered II-45Drug Encapsulation II-45High Level of Specificity II-45Increase in Drug Solubility and Uptake II-45Greater Usage Flexibility II-46Impact On Molecular Diagnostic Imaging II-46Seeing The Unseen II-46Impact On Pharmaceutical Drug Formulations II-47Impact On Therapeutics II-48Silver Nanoparticles as Effective Antimicrobial Agents II-48Modern Day Nanomedicine: A Current Scenario II-49Nanomedicine: The Cynosure of All Eyes II-49Drug Delivery Systems Epitomized by Nanomedicine II-50Targeted NanoDrug Delivery & Release II-50Active and Passive Targeting Mechanisms in Drug Delivery II-51Sustained and Pulsatile Release Mechanisms in Drug Delivery II-51A Peek Into Potential Nanobio Enabled Drug Carriers II-51Micelles II-52Liposomes II-52Dendrimers & Liquid Crystals II-52Nanoparticles II-52Polymeric Nanoparticles II-53Hydrogels II-53Molecularly Imprinted Polymers II-53Microelectromechanical Systems (MEMS) II-53Nanosuspensions II-54Fullerenes: A Platform for GenX Drug Delivery II-54Types of Nano-Based Drug Delivery Systems, RelatedMaterials, and Structures II-55Dynamics of Regenerative Medicine II-55Tissue Engineering and Restorations II-56Nanotechnology Enabled Diagnostics II-57Promised Path Breaking Applications in Molecular Diagnostics& Imaging II-57In-Vitro Diagnostics II-58Nanoprobes & Implantable Devices in In-vivo Imaging II-59Nanocomposites in Molecular Labeling & Diagnostics II-60Laboratory-on-a-Chip - A Revolutionary Technology inBiomolecular Detection II-60Biosensors - Heralding New Opportunities in MolecularDiagnostics II-61Nanobiosensors - A New Approach to Diagnostics Testing II-61Despite Huge Potential Key Hurdles Remain inCommercialization II-62Magnetic Nanoparticles for Imaging Applications in MRI II-62Dendrimers Promise Milestone Applications in MRI II-62Conclusions II-63Gauging the Real World Impact of Nanobiotech On Cancer: A CaseStudy II-63Quantum Dots Cock a Snook at Traditional Anti-Body LabelingAgents II-64Chemotherapeutic Reengineering & Gene Therapy: New TreatmentRegimes II-64Laboratory-on-chip (LOC): A Platform for Cancer Diagnosis II-65
Be the first to review this article
